Inhibition of Matriptase Activity Results in Decreased Intestinal Epithelial Monolayer Integrity In Vitro.
Barrier dysfunction in inflammatory bowel diseases implies enhanced paracellular flux and lowered transepithelial electrical resistance (TER) causing effective invasion of enteropathogens or altered intestinal absorption of toxins and drug compounds. To elucidate the role of matriptase-driven cell surface proteolysis in the maintenance of intestinal barrier function, the 3-amidinophenylalanine-derived matriptase inhibitor, MI-432 was used on porcine IPEC-J2 cell monolayer. Studies with two fluorescent probes revealed that short (2 h) treatment with MI-432 caused an altered distribution of oxidative species between intracellular and extracellular spaces in IPEC-J2 cells. This perturbation was partially compensated when administration of inhibitor continued for up to 48 h. Significant decrease in TER between apical and basolateral compartments of MI-432-treated IPEC-J2 cell monolayers proved that matriptase is one of the key effectors in the maintenance of barrier integrity. Changes in staining pattern of matriptase and in localization of the junctional protein occludin were observed suggesting that inhibition of matriptase by MI-432 can also exert an effect on paracellular gate opening via modulation of tight junctional protein assembly. This study confirms that non-tumorigenic IPEC-J2 cells can be used as an appropriate small intestinal model for the in vitro characterization of matriptase-related effects on intestinal epithelium. These findings demonstrate indirectly that matriptase plays a pivotal role in the development of barrier integrity; thus matriptase dysfunction can facilitate the occurence of leaky gut syndrome observed in intestinal inflammatory diseases.
Szent István University, Faculty of Veterinary Science, Department of Pharmacology and Toxicology, Budapest, Hungary.
E
E
Pászti-Gere
Szent István University, Faculty of Veterinary Science, Department of Pharmacology and Toxicology, Budapest, Hungary.
S
S
McManus
Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
N
N
Meggyesházi
Semmelweis University, 1st Department of Pathology and Experimental Cancer Research, Budapest, Hungary.
P
P
Balla
Szent István University, Faculty of Veterinary Science, Department of Pharmacology and Toxicology, Budapest, Hungary.
P
P
Gálfi
Philipps University Marburg, Faculty of Pharmacy, Institute of Pharmaceutical Chemistry, Marburg, Germany.
T
T
Steinmetzer
D000818:Animals; D002460:Cell Line; D002462:Cell Membrane / Q000378:metabolism; D004847:Epithelial Cells / Q000378:metabolism*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000378:metabolism; D007413:Intestinal Mucosa / Q000378:metabolism*; D007421:Intestine, Small / Q000378:metabolism*; D062793:Occludin / Q000378:metabolism; D059748:Proteolysis; D012697:Serine Endopeptidases / Q000378:metabolism*; D013552:Swine; D019108:Tight Junctions / Q000378:metabolism
D062793:Occludin; D012697:Serine Endopeptidases; C485595:matriptase